WITHDRAWN: Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy-Reference-Cited by-同舟云学术

WITHDRAWN: Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy

Published:2013-08 Issue: Volume: Page:
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

El-Awady Mostafa K.,El Gendy Mohamed,Waked Imam,Tabll Ashraf A.,El Abd Yasmin,Bader El Din Noha,El Shenawy Reem,Allam Aleef,Abdelhafez Tawfeek H.,Dawood Reham M.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference27 articles.

1. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles;Yutani;Cancer Sci,2009

2. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers;Drane;Hum Vaccines,2009

3. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus;Feinstone;Clin Infect Dis,2012

4. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination;Klade;Vaccine,2012

5. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy;Yutani;Vaccine,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on “Reverse Vaccinology”: The Pathway from Genomes and Epitope Predictions to Tailored, Recombinant Vaccines;Vaccine Design;2021-12-17

2. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design;Viruses;2015-07-17

3. Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection;Frontiers in Microbiology;2014-10-06

4. T Cell Responses to Viral Infections â€“ Opportunities for Peptide Vaccination;Frontiers in Immunology;2014-04-16

5. Therapeutic vaccines against hepatitis C virus;Infection, Genetics and Evolution;2014-03